Wire · opportunities
Roche's Lunsumio delivers positive confirmatory trial readout in follicular lymphoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Roche's Lunsumio combined with lenalidomide met the primary endpoint in a phase 3 trial for earlier-line follicular lymphoma, showing improved progression-free survival versus rituximab plus lenalidomide. This could convert Lunsumio's accelerated approval into full approval and position it earlier in treatment lines.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Your biotech firm developing oncology treatments faces a higher bar to differentiate against Roche’s advancing Lunsumio, which may soon gain full approval and shift earlier into second-line follicular lymphoma treatment. Consider accelerating comparisons to existing doublet or triplet therapies now gaining market approval.
◆ Coverage
2 sources · 17 Sep 2026
◆ Related on Wire
◆ Topics